Cyclooxygenase-2 inhibitors in lung cancer

Prostanoids produced by the arachidonic acid pathway play an important role in multiple stages of carcinogenesis and progression of cancer. Cyclooxygenase (COX), which exists in 2 isoforms, is the rate-limiting enzyme in the COX pathway. Cyclooxygenase-1 is constitutively expressed in normal tissues...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2004-01, Vol.5 (4), p.245-253
Main Authors: Ramalingam, Sakkaraiappan, Belani, Chandra P
Format: Article
Language:English
Subjects:
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - enzymology
Carcinoma, Non-Small-Cell Lung - pathology
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors - pharmacology
Cyclooxygenase Inhibitors - therapeutic use
Drug Interactions
Humans
Isoenzymes - genetics
Isoenzymes - metabolism
Lung Neoplasms - drug therapy
Lung Neoplasms - enzymology
Lung Neoplasms - pathology
Membrane Proteins
Neoplasm Invasiveness
Neovascularization, Pathologic - enzymology
Neovascularization, Pathologic - genetics
Peroxidases - genetics
Peroxidases - metabolism
Prostaglandin-Endoperoxide Synthases - genetics
Prostaglandin-Endoperoxide Synthases - metabolism
RNA, Messenger - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostanoids produced by the arachidonic acid pathway play an important role in multiple stages of carcinogenesis and progression of cancer. Cyclooxygenase (COX), which exists in 2 isoforms, is the rate-limiting enzyme in the COX pathway. Cyclooxygenase-1 is constitutively expressed in normal tissues and is essential for several important physiologic functions. Cyclooxygenase-2 is selectively overexpressed in neoplastic and inflammatory tissues. Non-small-cell lung cancer (NSCLC), especially adenocarcinomas, overexpress COX-2, which contributes to the progression of malignancy by several mechanisms. This represents the basis of therapy with COX-2 inhibitors. Cyclooxygenase-2 inhibitors, which are currently in clinical use for the management of inflammatory arthritis, are well tolerated by patients. They exhibit anticancer activity by several mechanisms including induction of apoptosis, inhibition of angiogenesis, and decreased invasiveness and metastatic potential. These effects have been documented in several preclinical studies. Clinical efficacy of COX-2 inhibitors in the treatment of NSCLC is presently undergoing evaluation.
ISSN:1525-7304
DOI:10.3816/CLC.2004.n.006